XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues:          
Revenues $ 10,000   $ 16,000 $ 43,000 $ 389,000
Operating expenses:          
Research and development 950,000   5,236,000 5,775,000 15,637,000
General and administrative 1,237,000   1,625,000 4,444,000 4,845,000
Total operating expenses 2,187,000   6,861,000 10,219,000 20,482,000
Operating loss (2,177,000)   (6,845,000) (10,176,000) (20,093,000)
Other (expense) income:          
Foreign exchange gains (losses) 2,000   104,000 6,000 (58,000)
Interest (expense) income 8,000   50,000 (18,000) 243,000
Other income (expense), net     (9,000) 52,000 50,000
Total other (expense) income, net 10,000   145,000 40,000 235,000
Loss before taxes (2,167,000)   (6,700,000) (10,136,000) (19,858,000)
Income tax benefit 210,000   668,000 1,976,000 2,574,000
Net loss (1,957,000) $ (3,257,000) (6,032,000) (8,160,000) (17,284,000)
Dividend on convertible exchangeable preferred shares     (50,000)   (151,000)
Net loss applicable to common shareholders $ (1,957,000)   $ (6,082,000) $ (8,160,000) $ (17,435,000)
Redeemable common shareholders          
Basic and diluted earnings per common share:          
Net loss per share - basic     $ (0.48)   $ (1.39)
Net loss per share - diluted   $ 0.00 (0.48) $ 0.00 (1.39)
Common Stock          
Basic and diluted earnings per common share:          
Net loss per share - basic $ (0.18)   (0.48) (2.04) (1.39)
Net loss per share - diluted   $ (0.18) $ (0.48) $ (2.04) $ (1.39)
Clinical trial supply          
Revenues:          
Revenues $ 10,000   $ 16,000 $ 43,000 $ 389,000